Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.
Back
Optimizing Care Across the Continuum: Updates in the Detection and Treatment of Prostate Cancer
Expert oncologist discuss key data from 2023 on the detection and treatment of prostate cancer.
Optimizing Care Across the Continuum: Updates in the Detection and Treatment of Prostate Cancer
Episodes
All
All
EP. 2: Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression
Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.
Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.
Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
2
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
3
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
4
Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC
5